Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$

ABN		
91 06	4 820 408	
We (tl	ne entity) give ASX the following	information.
	1 - All issues st complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary Fully Paid Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	785,718
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary Fully Paid Shares

Name of entity

Alexium International Group Limited

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	A\$0.35 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of share to directors of the Company following shareholder approval dated 8 May 2018 (Resolutions 4-10) arising from participation in the placement dated 11 December 2017.
6a	Is the entity an *eligible entity	Yes
	that has obtained security holder approval under rule 7.1A?	
	If Yes, complete sections 6b – 6h	
	in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	15 November 2017
6c	Number of *securities issued	Nil
	without security holder approval under rule 7.1	1411
6d	Number of *securities issued	Nil
	with security holder approval under rule 7.1A	

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Nil	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
-	47 1 .	2414 2242	
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	24 May 2018	
	Cross reference: item 33 of Appendix 3B.		
		3. J	10
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	Number 345,443,598	+Class Fully Paid Ordinary Shares

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
1,500,000	Unlisted Options expiring 30 September 2020 exercisable at \$0.75
300,000	Unlisted Options expiring 4 November 2019 exercisable at \$0.75
300,000	Unlisted Options expiring 4 November 2019 exercisable at \$1.25
300,000	Unlisted Options expiring 4 November 2019 exercisable at \$1.75

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
	<u></u>	
14	⁺ Class of ⁺ securities to which the offer relates	N/A
	<u> </u>	
15	⁺ Record date to determine entitlements	N/A
	<u> </u>	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
	Closing date for receipt of acceptances or renunciations	N/A

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

32	of th	do security holders dispose eir entitlements (except by hrough a broker)?	N/A	
33	⁺ Issu	e date	N/A	
		Quotation of securit omplete this section if you are app		
34	Type (<i>tick</i> d	of ⁺ securities one)		
(a)		⁺ Securities described in Part	1	
(b)		-	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible	
Entities that have ticked box 34(a)				
Addit	cional	securities forming a new	class of securities	
Tick to docum		e you are providing the informat	ion or	
35			securities, the names of the 20 largest holders of the he number and percentage of additional ⁺ securities	
36			y securities, a distribution schedule of the additional mber of holders in the categories	
37	П	A copy of any trust deed for t	the additional ⁺ securities	

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify	N/A	
	that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number N/A	+Class N/A

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

M. Acquire

Date: 28 May 2018

Print name: Maja McGuire

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure capacity is calculated	ure from which the placement	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	303,827,998	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	284,750 Shares – Issued 18 August 2017	
	344,833 Shares – Issued 18 August 2017	
	175,000 Shares – Issued 18 August 2017	
	30,000 Shares – Issued 31 August 2017	
	30,000 Shares – Issued 31 August 2017	
	30,000 Shares – Issued 31 August 2017	
	30,000 Shares – Issued 31 August 2017	
	405,417 Shares – Issued 31 August 2017	
	1,095,000 Shares – Issued 31 August 2017	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval 185,000 Shares Issued 16 November 2017 400,000 Shares issued 15 December 2017 (shareholder approval dated 08/05/18) 29,514,282 Shares issued 15 December 2018 (shareholder approval dated 08/05/18) 785,718 Shares issued 24 May 2018 (shareholder approval dated 08/05/18) Number of partly paid *ordinary securities hare became fully paid in that 12 month period Note: Include only ordinary securities here — other classes of equity securities renot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid *ordinary securities cancelled during that 12 month period "A" Nil		
securities that became fully paid in that 12 month period Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	issued in that 12 month period with	400,000 Shares issued 15 December 2017 (shareholder approval dated 08/05/18) 29,514,282 Shares issued 15 December 2018 (shareholder approval dated 08/05/18) 785,718 Shares issued 24 May 2018
securities cancelled during that 12 month period	securities that became fully paid in that 12 month period Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate	Nil
" A " 63,692,799	securities cancelled during that 12 month	Nil
	"A"	63,692,799

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	9,553,920
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	4,255,319 Shares Reserved pursuant to the Purchase Warrant
• Under an exception in rule 7.2	
• Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	4,255,319
Step 4: Subtract "C" from ["A" x "Eplacement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	9,553,920
Note: number must be same as shown in Step 2	
Subtract "C"	4,255,319
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	5,298,601
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	63,692,799	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	6,369,280	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
 Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	0	
"E"	0	

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	0	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	6,369,280	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.